

IV. VON: EPA MUENCHEN 01

:16- : 17:07 :

01414298331-

89 23994465:# 4

16-06-2000

GB 009901211

09/673785

1

422 Rec'd PCT/PTO 20 OCT 2000

1 CLAIMS

- 2
- 3 1 A peptide factor derived from amino acid residues 33
- 4 to 42 of murine epidermal growth factor peptide or a
- 5 synthetic equivalent thereof wherein the peptide
- 6 factor is modified to protect it from proteolytic
- 7 degradation and the peptide binds to laminin
- 8 receptors wherein the modifications consist of at
- 9 least one modification chosen from the group
- 10 comprising; substitution of tyrosine by tyrosine
- 11 analogues and substitution of arginine by arginine
- 12 analogues,
- 13
- 14 2 A peptide as claimed in Claim 1 wherein the
- 15 peptide is further modified by at least one
- 16 modification chosen from the group comprising
- 17 capping the N terminal of the peptide, capping
- 18 the C terminal of the peptide and capping thiol
- 19 groups of cysteines.
- 20
- 21 3 A peptide as claimed in claims 1 or 2 wherein
- 22 tyrosine is substituted by Tic-OH.
- 23
- 24 4 A peptide as claimed in claims 1, 2 or 3 wherein
- 25 arginine is substituted by Citrulline.
- 26
- 27 5 Use of a peptide factor as claimed in any of the
- 28 preceding claims in the preparation of a medicament
- 29 to bind laminin receptors as an antagonist.
- 30
- 31 6 Use of a peptide factor as claimed in any of the
- 32 preceding claims in the preparation of a medicament
- 33 to bind laminin receptors as an agonist.
- 34
- 35 7 Use as claimed in claim 6 in the preparation of a
- 36 medicament for healing endothelial cell wounding.

006227 5342960

GB 009901211

2

AMENDED SHEET